Better Therapeutics Performance
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
The firm shows a Beta (market volatility) of -0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Better Therapeutics are expected to decrease at a much lower rate. During the bear market, Better Therapeutics is likely to outperform the market. Better Therapeutics right now shows a risk of 0.0%. Please confirm Better Therapeutics treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Better Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Better Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Better Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 22.3 M |
Better |
Better Therapeutics Relative Risk vs. Return Landscape
If you would invest 73.00 in Better Therapeutics on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Better Therapeutics or generate 0.0% return on investment over 90 days. Better Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Better, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Better Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Better Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Better Therapeutics, and traders can use it to determine the average amount a Better Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BTTX |
Based on monthly moving average Better Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Better Therapeutics by adding Better Therapeutics to a well-diversified portfolio.
Better Therapeutics Fundamentals Growth
Better OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Better Therapeutics, and Better Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Better OTC Stock performance.
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| EBITDA | (29.18 M) | ||||
| Cash And Equivalents | 29.68 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 14.88 M | ||||
| Debt To Equity | 0.81 % | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (26.08 M) | ||||
| Earnings Per Share | (1.10) X | ||||
| Total Asset | 22.94 M | ||||
| Retained Earnings | (111.5 M) | ||||
About Better Therapeutics Performance
Evaluating Better Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Better Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Better Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.Things to note about Better Therapeutics performance evaluation
Checking the ongoing alerts about Better Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Better Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Better Therapeutics is not yet fully synchronised with the market data | |
| Better Therapeutics has some characteristics of a very speculative penny stock | |
| Better Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (31.57 M) with loss before overhead, payroll, taxes, and interest of (674 K). | |
| Better Therapeutics currently holds about 29.68 M in cash with (26.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 53.0% of the company shares are held by company insiders |
- Analyzing Better Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Better Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Better Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Better Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Better Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Better Therapeutics' otc stock. These opinions can provide insight into Better Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |